Cyclooxygenase‐2 as a therapeutic target against human breast cancer: A comprehensive review

Abstract

AbstractCyclooxygenase‐2 (COX‐2) is a key aspect of the physiology and pathogenesis of various cancer types. Overexpression of this enzyme is responsible for the elevated prostaglandin production and characteristic feature of breast cancer. Inhibition of COX‐2 derived prostanoids facilitates anti‐inflammatory, analgesic, and antipyretic effects of non‐steroid anti‐inflammation drugs. The overexpression of COX‐2 is associated with inflammation, pain, and fever. The present study provides the updated relevant literature describing the role of well‐characterized isoforms of cyclooxygenase with particular emphasis on COX‐2, mechanism of action, the effect of the drug, combinatorial drugs, and microarray‐based differential expression analysis and network analysis. We have discussed the currently used combinatorial treatments and their challenges in breast cancer.This article is categorized under: Cancer > Computational Models Cancer > Molecular and Cellular Physiology